Lepsitam (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A in the brain. This binding modulates the release of neurotransmitters, stabilizing neuronal firing and decreasing hyper‑excitability that can lead to seizure activity.

The appropriate dose of Lepsitam is determined individually by a qualified prescriber based on the patient’s age, weight, renal function, and seizure type. Dosage adjustments are made according to clinical response and tolerability.

Safety data for levetiracetam in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting or continuing therapy.

To request Lepsitam, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lepsitam (levetiracetam) offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It is generally well‑tolerated, has fewer drug‑enzyme interactions, and is often chosen when patients need a medication with a simpler metabolic profile.

Lepsitam should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme heat to maintain its stability and potency.

Lepsitam is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include severe allergic reactions, skin conditions such as Stevens‑Johnson syndrome, mood changes including depression or suicidal thoughts, and rare blood disorders. Patients should seek immediate medical attention if they experience rash, fever, mood alterations, or signs of an allergic reaction.

Lepsitam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Patients with uncontrolled psychiatric disorders or those who have experienced severe reactions to similar antiepileptic agents should discuss alternatives with their healthcare provider.